EP4132930
CRYSTALLINE FORMS OF (9, 135S)-13- {4-[5-CHLORO-2-(4-CHLORO-1H,2,3- TRIAZOL- 1 -YL)PHENYL] -6-OXO- 1,6-DIHYDROPYRIMIDIN- 1-YL}-3-(DIFLUOROMETHYL)-9-METHYL-3,4,7,15- TETRAAZATRICYCLO [ 12.3.1.0] OCTADE
Status:
EP einkaleyfi: EP einkaleyfi tilnefnt til gildistöku á ÍslandiEP appl. date:
9.4.2021EP published:
20.5.2026EP application number:
21722085.4
EPO information:
European Patent Register
Max expiry date:
8.4.2041Expiry date:
8.4.2027
Title in English:
CRYSTALLINE FORMS OF (9, 135S)-13- {4-[5-CHLORO-2-(4-CHLORO-1H,2,3- TRIAZOL- 1 -YL)PHENYL] -6-OXO- 1,6-DIHYDROPYRIMIDIN- 1-YL}-3-(DIFLUOROMETHYL)-9-METHYL-3,4,7,15- TETRAAZATRICYCLO [ 12.3.1.0] OCTADELanguage of the patent:
English
Timeline
Today
9.4.2021EP application
20.5.2026EP Publication
8.4.2027Expires
Owner
Name:
Bristol-Myers Squibb CompanyAddress:
Route 206 and Province Line Road, Princeton, NJ 08543, US
Name:
JANSSEN Pharmaceutica NVAddress:
Turnhoutseweg 30, 2340 Beerse, BE
Inventor
Name:
DILGER, Andrew K.Address:
Princeton, New Jersey 08543, US
Name:
GALELLA, Michael A.Address:
Princeton, New Jersey 08543, US
Name:
SMITH, DanielAddress:
Princeton, New Jersey 08543, US
Name:
ZIEMBA, Theresa M.Address:
Princeton, New Jersey 08543, US
Name:
LÜDEKER, DavidAddress:
2340 Beerse, BE
Name:
XIOURAS, ChristosAddress:
2340 Beerse, BE
Name:
AHUJA, DipaliAddress:
2340 Beerse, BE
Name:
CLEEREN, Dirk Angelina J.Address:
2340 Beerse, BE
Priority
Number:
202063008161 PDate:
10.4.2020Country:
US
Classification
Categories:
C07D 471/18, A61P 7/02, A61K 31/439